# A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)

> **NCT00092391** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1997 (actual)

## Conditions studied

- Measles
- Mumps
- Rubella
- Varicella

## Interventions

- **BIOLOGICAL:** Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live
- **BIOLOGICAL:** Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)

## Key facts

- **NCT ID:** NCT00092391
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-02
- **Primary completion:** 2001-07
- **Final completion:** 2001-07
- **Target enrollment:** 1997 (ACTUAL)
- **Last updated:** 2015-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00092391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00092391, "A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00092391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*